Shionogi & Co., Ltd.
Stock Price Chart
2026/03/03 UpdatedPrice Trend
2026/03/03 UpdatedPrice & Trading Details
2026/03/03 UpdatedPRICE
TRADING
Analyst Recommendations 9 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
11.9M | +58.60% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
10.9M | +0.18% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
7.2M | -3.61% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
7.0M | +2.59% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
5.2M | -0.56% | |
|
Fidelity Concord Street Trust-Fidelity International Index Fund
|
2.7M | +1.46% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
435.5K | +54.26% |
Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥66 | +16.5% |
| 2024 | ¥57 | +13.3% |
| 2023 | ¥50 | +25.0% |
| 2022 | ¥40 | +11.1% |
| 2021 | ¥36 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥335,138M | ¥426,684M | ¥435,081M | ¥438,268M |
| Gross Profit | ¥279,722M | ¥364,437M | ¥377,479M | ¥374,441M |
| Operating Income | ¥110,312M | ¥149,004M | ¥153,312M | ¥156,604M |
| Pretax Income | ¥127,109M | ¥224,832M | ¥204,984M | ¥209,777M |
| Net Income | ¥114,185M | ¥184,965M | ¥162,030M | ¥170,435M |
| EPS | ¥126.21 | ¥207.03 | ¥186.11 | - |
| Operating Margin | 32.92% | 34.92% | 35.24% | 35.73% |
| Balance Sheet | ||||
| Total Assets | ¥1,150,601M | ¥1,311,800M | ¥1,416,918M | ¥1,535,349M |
| Total Equity | ¥975,661M | ¥1,100,046M | ¥1,235,325M | ¥1,361,924M |
| Total Liabilities | ¥174,940M | ¥211,754M | ¥181,593M | ¥173,425M |
| Cash | ¥254,420M | ¥309,224M | ¥358,090M | ¥374,795M |
| Interest-bearing Debt | ¥6,674M | ¥9,411M | ¥11,620M | ¥21,882M |
| Equity Ratio | 84.80% | 83.86% | 87.18% | 88.70% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.02 |
| Cash Flow | ||||
| Operating CF | ¥102,068M | ¥177,867M | ¥154,284M | ¥195,460M |
| Investing CF | -¥96,204M | -¥48,292M | ¥5,922M | -¥116,080M |
| Financing CF | -¥36,615M | -¥84,123M | -¥126,853M | -¥64,908M |
| Free CF | ¥70,504M | ¥140,680M | ¥126,017M | ¥143,357M |
| Efficiency | ||||
| ROE | 11.70% | 16.81% | 13.12% | 12.51% |
| ROA | 9.92% | 14.10% | 11.44% | 11.10% |
Latest IR Information
-
Regarding the Application for Manufacturing and Marketing Approval for the Addition of Lotion Formulation of Atopic Dermatitis Treatment "Collectim®" in Japan
Shionogi & Co., Ltd. has applied for manufacturing and marketing approval of the 0.5% lotion formulation of the atopic dermatitis treatment "Collectim®." Safety and bioequivalence were confirmed through Phase 1 skin safety and Phase 3 bioequivalence studies.
Read more -
Notice of Basic Policy Decision on the Absorption-Type Merger of Our Wholly Owned Subsidiary Torii Pharmaceutical Co., Ltd.
Shionogi & Co., Ltd. has decided on the basic policy to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. through a merger effective April 1, 2027.
Read more -
Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 [IFRS] (Consolidated)
For the third quarter of the fiscal year ending March 2026, revenue was 360,684 million yen (8.1% YoY increase), operating income was 148,739 million yen (15.1% YoY increase), and net income attributable to owners of parent for the quarter was...
Read more -
Supplementary Materials for Q3 FY March 2026 Financial Results
In the third quarter of the fiscal year ending March 2026, Shionogi & Co., Ltd. achieved revenue of 360.7 billion yen (8.1% YoY increase), operating income of 148.7 billion yen (15.1% YoY increase), and quarterly profit of 158.2 billion yen...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥3,118
Rating Score: 2.60 (Based on 9 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Osaka, Japan.